Stephen J Kerr,* Andrea Mant,† Fiona E Horn,‡ Kevin McGeechan,§ Geoffrey P Sayer¶
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328-331. <eMJA full text>
- 2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
- 3. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283-292.
- 4. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795-806.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
In 1997, Associate Professor Andrea Mant provided consultancy advice on Quality Use of Medicines to Merck Sharp & Dohme.